Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01776723 |
Title | A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib |
Recruitment | Completed |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | United States | Details | |
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | United States | Details | |
Brigham and Women's Hospital | Boston | Massachusetts | 02115 | United States | Details | |
Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
Weill Medical College of Cornell | New York | New York | 10021 | United States | Details | |
Cleveland Clinic | Cleveland | Ohio | 44106 | United States | Details |